Basso F, Rocchetti F, Rodriguez S, Nesterova M, Cormier F, Stratakis C A, Ragazzon B, Bertherat J, Rizk-Rabin M
INSERM U1016, CNRS (UMR 8104), Institut Cochin, Université Paris Descartes, Sorbonne Paris Cité, Faculté de Médecine, Paris, France, Paris, France.
National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, USA.
Horm Metab Res. 2014 Nov;46(12):883-8. doi: 10.1055/s-0034-1389951. Epub 2014 Sep 30.
The cyclic AMP/protein kinase A signaling cascade is one of the main pathways involved in the pathogenesis of adrenocortical tumors. The PKA R1A and R2B proteins are the most abundant regulatory subunits in endocrine tissues. Inactivating mutations of PRKAR1A are associated with Carney complex and a subset of sporadic tumors and the abundance of R2B protein is low in a subset of secreting adrenocortical adenomas. We previously showed that PRKAR1A and PRKAR2B inactivation have anti-apoptotic effects on the adrenocortical carcinoma cell line H295R. The aim of this study was to compare the effects of PRKAR1A and PRKAR2B depletion on cell proliferation, apoptosis, cell signaling pathways, and cell cycle regulation. We found that PRKAR2B depletion is compensated by an upregulation of R1A protein, whereas PRKAR1A depletion has no effect on the production of R2B. The depletion of either PRKAR1A or PRKAR2B promotes the expression of Bcl-xL and resistance to apoptosis; and is associated with a high percentage of cells in S and G2 phase, activates PKA and MEK/ERK pathways, and impairs the expression of IkB leading to activate the NF-κB pathway. However, we observed differences in the regulation of cyclins. The depletion of PRKAR1A leads to the accumulation of cyclin D1 and p27kip, whereas the depletion of PRKAR2B promotes the accumulation of cyclin A, B, cdk1, cdc2, and p21Cip. In conclusion, although the depletion of PRKAR1A and PRKAR2B in adrenocortical cells has similar effects on cell proliferation and apoptosis; loss of these PKA subunits differentially affects cyclin expression.
环磷酸腺苷/蛋白激酶A信号级联反应是肾上腺皮质肿瘤发病机制中涉及的主要途径之一。蛋白激酶A R1A和R2B蛋白是内分泌组织中最丰富的调节亚基。PRKAR1A的失活突变与卡尼综合征及一部分散发性肿瘤相关,并且在一部分分泌性肾上腺皮质腺瘤中R2B蛋白丰度较低。我们之前表明PRKAR1A和PRKAR2B失活对肾上腺皮质癌细胞系H295R具有抗凋亡作用。本研究的目的是比较PRKAR1A和PRKAR2B缺失对细胞增殖、凋亡、细胞信号通路及细胞周期调控的影响。我们发现PRKAR2B缺失可通过R1A蛋白上调得到补偿,而PRKAR1A缺失对R2B的产生没有影响。PRKAR1A或PRKAR2B的缺失均促进Bcl-xL的表达及对凋亡的抵抗;并与S期和G2期高比例细胞相关,激活蛋白激酶A和MEK/ERK通路,且损害IkB的表达从而导致NF-κB通路激活。然而,我们观察到细胞周期蛋白调控存在差异。PRKAR1A的缺失导致细胞周期蛋白D1和p27kip积累,而PRKAR2B的缺失促进细胞周期蛋白A、B、细胞周期蛋白依赖性激酶1、细胞分裂周期蛋白2和p21Cip积累。总之,尽管肾上腺皮质细胞中PRKAR1A和PRKAR2B的缺失对细胞增殖和凋亡有相似影响;但这些蛋白激酶A亚基的缺失对细胞周期蛋白表达的影响存在差异。